Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Research from Medical University of Vienna, Clinical Institute of Medical and Chemical Laboratory Diagnostics reveals new findings on cancer gene therapy
March 18th, 2008
A new study, 'Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines,' is now available. According to recent research published in the journal Cancer Letters, "Pancreatic cancer still remains a treatment-refractory cancer. Standard therapy for metastatic cancer is gemcitabine (dFdC) chemotherapy." "Since heavy water (deuterium oxide, D2O) was shown to be active in pancreatic cancer in vitro, we examined the simultaneous or sequential cytotoxic effects of D2O and dFdC in pancreatic cancer cell lines (AsPC-1, BxPC-3, and PANC-1). Moreover, we investigated the effect of D2O treatment on the colony formation of peripheral blood...
Source: Cancer Weekly (2008-03-18)
|
